Cystic fibrosis, vector-mediated gene therapy, and relevance of toll-like receptors: A review of problems, progress, and possibilities

Current Gene Therapy

Volumn 8, Issue 3, 2008, Pages 201-207

  Atkinson, Timothy J ^a  

^a Biomedical and Pharmaceutical Consultant   (United Kingdom)

Author keywords

Cystic fibrosis; Gene therapy; Nonviral vectors; Progress; Toll like receptors; Transfection; Viral vectors

Indexed keywords

ADENOVIRUS VECTOR; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; DENUFOSOL; DURAMYCIN; LENTIVIRUS VECTOR; LIPOSOME; NAKED DNA; PARVOVIRUS VECTOR; POLYMER; RETROVIRUS VECTOR; TOLL LIKE RECEPTOR; TRANSMEMBRANE CONDUCTANCE REGULATOR; VIRUS VECTOR;

BONE MARROW CELL; CELL THERAPY; CLINICAL TRIAL; CORONAVIRUS; CYSTIC FIBROSIS; DNA REPAIR; DRUG EFFICACY; DRUG SAFETY; EMBRYONIC STEM CELL; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENETIC STABILITY; GENETIC TRANSFECTION; HUMAN; IMMUNE RESPONSE; LUNG FUNCTION; MESENCHYMAL STEM CELL; NONVIRAL GENE DELIVERY SYSTEM; PATHOGENESIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; SENDAI VIRUS; TRANSGENE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GENE THERAPY; GENETIC VECTORS; HUMANS; TOLL-LIKE RECEPTORS; TRANSFECTION;

EID: 48249099755     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652308784746468     Document Type: Review

References (67)

1. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245: 1066-1073 (1989).
2. Curry MP, Hegarty JE. The gallbladder and biliary tract in cystic fibrosis. Curr Gastroenterol Rep 7(2): 147-53 (2005).
3. Knowlton RG, Cohen-Haguenauer O, Van Cong N, et al. A polymorphic DNA marker linked to cystic fibrosis is located on chromosome 7. Nature 318: 380-382 (1985).
4. White R, Woodward S, Leppert M et al. A closely linked genetic marker for cystic fibrosis. Nature 318: 382-384 (1985).
5. Wainwright BJ, Scambler PJ, Schmodtke J, et al. Localization of cystic fibrosis locus to human chromosome 7cen-q22. Nature 318: 384-385 (1985).
6. Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: Genetic analysis. Science 245:1073-1079 (1989).
7. Larson JE, Cohen JC. Developmental paradigm for early features of cystic fibrosis. Pediatr Pulmonol 40(5): 371-377 (2005).
8. Matsui H, Grubb BR, Tarran R, et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 95: 1005-1015 (1998).
9. Imundo L, Barasch J, Prince A, Al-Awqati Q. Cystic fibrosis epithelial cells have a receptor for pathogenic bacteria on their apical surface. Proc Natl Acad Sci USA 92: 3019-3023 (1995).
10. Collins FS. Cystic fibrosis: molecular biology and therapeutic implications. Science 256(5058): 774-779 (1992).
11. Johnson L, Olsen J, Sarkadi B, et al. Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nat Genet 2: 21-5 (1992).
12. Ramalho AS, Beck S, Meyer M, et al. Five percent of normal cystic fibrosis transmembrane conductance regulator mRNA ameliorates the severity of pulmonary disease in cystic fibrosis. Am J Respir Cell Mol Biol 5: 619-27 (2002).
13. Vadolas J, Williamson R, Ioannou PA. Gene therapy for inherited lung disorders: an insight into pulmonary defence. Pulmon Pharmacol Therapeut 15: 61-72 (2002).
14. Montier T, Delépine P, Marianowski R, et al. CFTR transgene expression in primary DeltaF508 epithelial cell cultures from human nasal polyps following gene transfer with cationic phosphonolipids. Mol Biotechnol 26(3): 193-206 (2004).
15. Conese M, Boyd AC, Di Gioia S, et al. Genomic context vectors and artificial chromosomes for cystic fibrosis gene therapy. Curr Gene Ther 7(3): 175-187 (2007).
16. Weiss DJ, Pilewski JM. The status of gene therapy for cystic fibrosis. Semin Respir Crit Care Med 24(6): 749-70 (2003).
17. Anson DS, Smith GJ, Parsons DW. Gene therapy for cystic fibrosis airway disease- is clinical success imminent? Curr Gene Ther 6(2): 161-179 (2006).
18. Pickles RJ. Physical and biological barriers to viral vector-mediated delivery of genes to the airway epithelium. Proc Am Thorac Soc 1(4): 302-308 (2004).
19. Zabner J, Petersen DM, Puga AP, et al. Safety and efficacy of repetitive adenovirus-mediated transfer of CFTR cDNA to airway epithelia of primates and cotton rats. Nat Genet 6: 75-83 (1994).
20. Drumm ML, Pope HA, Cliff WH, et al. Correction of the cystic fibrosis defect in vitro by retrovirus-mediated gene transfer. Cell 62: 1227-1233 (1990).
21. Rich DP, Anderson MP, Gregory RJ, et al. Expression of cystic fibrosis transmembrane conductance regulator corrects defective chloride channel regulation in cystic fibrosis airway epithelial cells. Nature 347: 358-363 (1990).
22. Alton EW, Middleton PG, Caplen NJ, et al. Noninvasive liposome-mediated gene delivery can correct the ion transport defect in cystic fibrosis mutant mice. Nat Genet 5: 135-142 (1993).
23. Caplen NJ, Alton EW, Middleton PG, et al. Liposomemediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nat Med 1: 39-46 (1995).
24. Farhood H, Gao X, Son K, et al. Cationic liposomes for direct gene transfer in therapy of cancer and other diseases. Ann N Y Acad Sci 716: 23-34 (1994).
25. Wang G, Deering C, Macke M, et al. Human coronavirus 229E infects polarized airway epithelia from the apical surface. J Virol 74(19): 9234-9239 (2000).
26. Zhang L, Peeples ME, Boucher RC, et al. Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J Virol 76(11): 5654-66 (2002).
27. Kolb M, Martin G, Medina M, et al. Gene therapy for pulmonary diseases. Chest 130: 879-884 (2006).
28. Ziady AG, Davis PB. Current prospects for gene therapy of cystic fibrosis. Curr Opin Pharmacol 6(5): 515-521 (2006).
29. Lassance RM, Pássaro CP, Martini SV, et al. Does the use of recombinant AAV2 in pulmonary gene therapy damage lung function? Respir Physiol Neurobiol 160(1): 91-98 (2008).
30. Griesenbach U, Geddes DM, Alton EW. Advances in cystic fibrosis gene therapy. Curr Opin Pulm Med 10(6): 542-546 (2004).
31. Flotte TP, Afione SA, Conrad C, et al. Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc Natl Acad Sci USA 90(22): 10613-10617 (1993).
32. Olsen JC, Johnson LG, Stutts MJ, et al. Correction of the apical membrane chloride permeability defect in polarized cystic fibrosis airway epithelia following retroviral-mediated gene transfer. Hum Gene Ther 3(3): 253-266 (1992).
33. Moss RB, Rodman D, Spencer LT, et al. Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis trans-membrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Chest 125(2): 509-521 (2004).
34. Moss RB, Milla C, Colombo J, et al. Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial. Hum Gene Ther 18(8): 726-32 (2007).
35. Halbert CL, Allen JM, Miller AD. Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors. J Virol 75(14): 6615-6624 (2001).
36. Lee TW, Matthews DA, Blair GE. Novel molecular approaches to cystic fibrosis gene therapy. Biochem J 387(Pt 1): 1-15 (2005).
37. van Ginkel FW, Liu C, Simecka JW, et al. Intratracheal gene delivery with adenoviral vector induces elevated systemic IgG and mucosal IgA antibodies to adenovirus and beta-galactosidase. Hum Gene Ther 6(7): 895-903 (1995).
38. van Ginkel FW, McGhee JR, Liu C, et al. Adenoviral gene delivery elicits distinct pulmonary-associated T helper cell responses to the vector and to its transgene. J Immunol 159(2): 685-693 (1997).
39. Croyle MA, Chirmule N, Zhang Y, Wilson JM. "Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J Virol 75(10): 4792-4801 (2001).
40. Duan D, Yue Y, Engelhardt JF. Expanding AAV packaging capacity with trans-splicing or overlapping vectors: a quantitative comparison. Mol Ther 4(4): 383-391 (2001).
41. Romano G. Current development of adeno-associated viral vectors. Drug News Perspect 18(5): 311-316 (2005).
42. Virella-Lowell I, Zusman B, Foust K, et al. Enhancing rAAV vector expression in the lung. J Gene Med 7(7): 842-50 (2005).
43. Ostedgaard LS, Rokhlina T, Karp PH, et al. A shortened adeno-associated virus expression cassette for CFTR gene transfer to cystic fibrosis airway epithelia. Proc Natl Acad Sci USA 102(8): 2952-2957 (2005).
44. Ferrari S, Griesenbach U, Iida A, et al. Sendai virus-mediated CFTR gene transfer to the airway epithelium. Gene Ther 14(19): 1371-1379 (2007).
45. Sinn PL, Goreham-Voss JD, Arias AC, et al. Enhanced gene expression conferred by stepwise modification of a nonprimate lentiviral vector. Hum Gene Ther 18(12): 1244-1252 (2007).
46. Davis PB, Cooper MJ. Vectors for airway gene delivery. AAPS J 9(1): E11-E17 (2007).
47. Bastian A, Schaefer H. Human α-defensin-1 (HNP-1) inhibits adenoviral infection in vitro. Regulat Peptides 101: 157-161 (2001).
48. Morsy MA, Gu M, Motzel S, et al. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc Natl Acad Sci USA 95(14): 7866-7871 (1998).
49. Cormet-Boyaka E, Jablonsky M, Naren AP, et al. Rescuing cystic fibrosis transmembrane conductance regulator (CFTR)-processing mutants by transcomplementation. Proc Natl Acad Sci USA 101(21): 8221-8226 (2004).
50. Montier T, Delépine P, Pichon C, et al. Non-viral vectors in cystic fibrosis gene therapy: progress and challenges. Trends Biotechnol 22(11):586-92 (2004).
51. Giangreco A, Reynolds SD, Stripp BR. Terminal bronchioles harbor a unique airway stem cell population that localizes to the bronchoalveolar duct junction. Am J Pathol 161: 173-182 (2002).
52. Kim CF, Jackson EL, Woolfenden AE, et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 121: 823-835 (2005).
53. Wang G, Bunnell BA, Painter RG, et al. Adult stem cells from bone marrow stroma differentiate into airway epithelial cells: potential therapy for cystic fibrosis. Proc Natl Acad Sci USA 102(1): 186-191 (2005).
54. Coraux C, Nawrocki-Raby B, Hinnrasky J, et al. Embryonic stem cells generate airway epithelial tissue. Am J Respir Cell Mol Biol 32: 87-92 (2005).
55. Conese M, Rejman J. Stem cells and cystic fibrosis. J Cystic Fibrosis 5: 141-143 (2006).
56. Ratjen F. New pulmonary therapies for cystic fibrosis. Curr Opin Pulm Med 13(6): 541-546 (2007).
57. Zaldumbide A, Hoeben RC. How not to be seen: immune-evasion strategies in gene therapy. Gene Ther 15(4): 239-246 (2008).
58. Diamond G, Legarda D, Ryan LK. The innate immune response of the respiratory epithelium. Immunol Rev 173: 27-38 (2000).
59. Kopp EB, Medzhitov R. The toll-receptor family and control of innate immunity. Curr Opin Immunol 11: 13-18 (1999).
60. Atkinson TJ. Toll-like receptors, transduction-effector pathways and disease diversity - evidence of an immunobiological paradigm explaining all human illness? Int Rev Immunol (2008) (in press).
61. Fu Z, Bettega K, Carroll S, et al. Role of Ca2+ in responses of airway epithelia to Pseudomonas aeruginosa, flagellin, ATP, and thapsigargin. Am J Physiol Lung Cell Mol Physiol 292(1): L353-64 (2007).
62. Muir A, Soong G, Sokol S, et al. Toll-like receptors in normal and cystic fibrosis airway epithelial cells. Am J Respir Cell Mol Biol 30(6): 777-783 (2004).
63. Shuto T, Furuta T, Oba M, et al. Promoter hypomethylation of Toll-like receptor-2 gene is associated with increased proinflammatoryresponse toward bacterial peptidoglycan in cystic fibrosis bronchial epithelial cells. FASEB J 20(6): 782-784 (2006).
64. Greene CM, Carroll TP, Smith SG, et al. TLR-induced inflammation in cystic fibrosis and non-cystic fibrosis airway epithelial cells. J Immunol 174(3): 1638-1646 (2005).
65. Hauber HP, Tulic MK, Tsicopoulos A, et al. Toll-like receptors 4 and 2 expression in the bronchial mucosa of patients with cystic fibrosis. Can Respir J 12(1): 13-18 (2005).
66. Yu ZY, McKay K, van Asperen P, et al. Lentivirus vector-mediated gene transfer to the developing bronchiolar airway epithelium in the fetal lamb. J Gene Med 9(6):429-439 (2007).
67. Rosenecker J, Huth S, Rudolph C. Gene therapy for cystic fibrosis lung disease: current status and future perspectives. Curr Opin Mol Ther 8(5): 439-445 (2006).